

HCS HB 95 -- CO-PAYMENTS FOR PRESCRIPTION DRUGS

SPONSOR: Schaaf

COMMITTEE ACTION: Voted "do pass by consent" by the Committee on Healthcare Transformation by a vote of 10 to 0.

This substitute specifies that when the usual and customary retail price of a prescription drug is less than the co-payment applied by a health maintenance organization or health insurer, the enrollee is only required to pay the usual and customary retail price of the prescription drug and there will be no further charge to the enrollee or plan sponsor for the prescription.

FISCAL NOTE: No impact on state funds in FY 2010, FY 2011, and FY 2012.

PROPOSERS: Supporters say that the bill gives every advantage to the patient and addresses an issue that should be standard practice.

Testifying for the bill were Representative Schaaf; Coventry Health Care of Kansas, Incorporated; and United Healthcare.

OPPOSERS: There was no opposition voiced to the committee.